Cargando…
Is Reducing Ovarian Volume in Polycystic Ovarian Syndrome Patients after Administration of Metformin Associated with Improving Cardiovascular Risk Factors?
BACKGROUND: Women with polycystic ovary syndrome (PCOS) are at increased risk for cardiovascular (CV) and metabolic disorders. There is a close relationship between elevated androgen plasma levels and the ultrasound findings of stromal hypertrophy. In randomized trials, the administration of metform...
Autores principales: | Gharakhani, Mohsen, Neghab, Nosrat, Farimani, Marzie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royan Institute
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059955/ https://www.ncbi.nlm.nih.gov/pubmed/24963365 |
Ejemplares similares
-
Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
por: Farimani Sanoee, Marzieh, et al.
Publicado: (2011) -
Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis
por: Peng, Qingjie, et al.
Publicado: (2023) -
Metformin effects on zonulin level in polycystic ovarian women
por: Ibrahim, Manal, et al.
Publicado: (2020) -
Dehydroepiandrosterone-Sulfate, Insulin Resistance and Ovarian Volume Estimation in Patients With Polycystic Ovarian Syndrome
por: Christodoulaki, Chrysi, et al.
Publicado: (2017) -
Metformin—clomiphene citrate vs. clomiphene citrate alone: Polycystic ovarian syndrome
por: Ayaz, Aqueela, et al.
Publicado: (2013)